top of page

Daiichi Sankyo's global head of R&D talks antibody-drug conjugates and more at the company's "Pharma Day" event in Kendall Square

  • blonca9
  • Jul 16, 2024
  • 1 min read

From a partnering event being held at MassBio's HQ in Kendall Square, Ken Takeshita describes Daiichi's targets under development beyond HER2 and TROP2, plus what the company is looking at outside of ADCs.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page